Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Vera Therapeutics (Nasdaq: VERA), a late clinical-stage biotechnology company specializing in immunological disease treatments, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, scheduled for January 12-16, 2025.
The company's management team will deliver a presentation on Monday, January 13, 2025, at 4:30 PM PST. The presentation will be accessible via webcast, and investors can view it through the J.P. Morgan meetings platform. Additionally, the management team will engage in one-on-one meetings with investors during the conference.
A replay of the presentation will remain available for 90 days through the 'Investor Calendar' section of Vera Therapeutics' website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, VERA gained 0.21%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BRISBANE, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present at the 43rd Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 12 – 16, 2025. The management team will also participate in one-on-one investor meetings.
Presentation Details:
Date: Monday, January 13, 2025
Time: 4:30 PM PST
Webcast: https://jpmorgan.metameetings.net/events/healthcare25
A replay of the event will be available for 90 days and can be accessed by visiting the “Investor Calendar” section of the Vera Therapeutics website.
About Vera
Vera Therapeutics is a late clinical-stage biotechnology company focused on developing treatments for serious immunological diseases. Vera’s mission is to advance treatments that target the source of immunological diseases in order to change the standard of care for patients. Vera’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B-cell Activating Factor (BAFF) and A PRoliferation-Inducing Ligand (APRIL), which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases, including IgAN, also known as Berger’s disease, and lupus nephritis. In addition, Vera is evaluating additional diseases where the reduction of autoantibodies by atacicept may prove medically useful. Vera is also developing MAU868, a monoclonal antibody designed to neutralize infection with BK virus (BKV), a polyomavirus that can have devastating consequences in certain settings such as kidney transplant. Vera retains all global developmental and commercial rights to atacicept and MAU868. For more information, please visit www.veratx.com.
For more information, please contact:
Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com
Media Contact:
Madelin Hawtin
LifeSci Communications
MHawtin@lifescicomms.com
FAQ
When is Vera Therapeutics (VERA) presenting at the 2025 J.P. Morgan Healthcare Conference?
How long will the VERA J.P. Morgan Healthcare Conference presentation replay be available?
Where can investors access Vera Therapeutics' (VERA) J.P. Morgan Healthcare Conference presentation?
What type of investor engagement is VERA offering at the 2025 J.P. Morgan Healthcare Conference?
What is the duration of the 2025 J.P. Morgan Healthcare Conference where VERA is presenting?
